News Image

NASDAQ:GILD is probably undervalued for the fundamentals it is displaying.

By Mill Chart

Last update: Jan 4, 2024

Discover GILEAD SCIENCES INC (NASDAQ:GILD), an undervalued stock highlighted by our stock screener. NASDAQ:GILD showcases solid financial health and profitability while maintaining an appealing valuation. We'll explore the details.

Valuation Analysis for NASDAQ:GILD

To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:GILD has achieved a 7 out of 10:

  • The Price/Earnings ratio is 11.94, which indicates a very decent valuation of GILD.
  • 98.31% of the companies in the same industry are more expensive than GILD, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 25.54, GILD is valued rather cheaply.
  • A Price/Forward Earnings ratio of 11.24 indicates a reasonable valuation of GILD.
  • Based on the Price/Forward Earnings ratio, GILD is valued cheaper than 98.65% of the companies in the same industry.
  • GILD is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 20.54, which is the current average of the S&P500 Index.
  • Based on the Enterprise Value to EBITDA ratio, GILD is valued cheaper than 97.30% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, GILD is valued cheaply inside the industry as 98.31% of the companies are valued more expensively.
  • GILD has an outstanding profitability rating, which may justify a higher PE ratio.

Profitability Examination for NASDAQ:GILD

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:GILD, the assigned 8 is noteworthy for profitability:

  • Looking at the Return On Assets, with a value of 9.42%, GILD belongs to the top of the industry, outperforming 97.13% of the companies in the same industry.
  • GILD's Return On Equity of 26.33% is amongst the best of the industry. GILD outperforms 98.14% of its industry peers.
  • The Return On Invested Capital of GILD (12.57%) is better than 96.80% of its industry peers.
  • The 3 year average ROIC (11.27%) for GILD is below the current ROIC(12.57%), indicating increased profibility in the last year.
  • GILD's Profit Margin of 21.45% is amongst the best of the industry. GILD outperforms 97.64% of its industry peers.
  • The Operating Margin of GILD (30.16%) is better than 97.64% of its industry peers.
  • With an excellent Gross Margin value of 78.81%, GILD belongs to the best of the industry, outperforming 85.83% of the companies in the same industry.

Health Assessment of NASDAQ:GILD

Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:GILD has achieved a 5 out of 10:

  • GILD's Altman-Z score of 2.87 is fine compared to the rest of the industry. GILD outperforms 71.16% of its industry peers.
  • GILD has a debt to FCF ratio of 3.18. This is a good value and a sign of high solvency as GILD would need 3.18 years to pay back of all of its debts.
  • The Debt to FCF ratio of GILD (3.18) is better than 95.11% of its industry peers.

ChartMill's Evaluation of Growth

ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NASDAQ:GILD scores a 4 out of 10:

  • GILD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.13%, which is quite good.
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

Our Decent Value screener lists more Decent Value stocks and is updated daily.

Check the latest full fundamental report of GILD for a complete fundamental analysis.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

GILEAD SCIENCES INC

NASDAQ:GILD (4/19/2024, 3:58:09 PM)

After market: 66.76 0 (0%)

66.76

+0.6 (+0.91%)

GILD News

News Image7 hours ago - Market News VideoInteresting GILD Put And Call Options For July 19th
News Imagea day ago - Zacks Investment ResearchGilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Gilead Sciences (GILD) closed at $66.16 in the latest trading session, marking a -1.15% move from the prior day.

News Imagea day ago - Zacks Investment ResearchAnalysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News Image3 days ago - ChartmillWhy the dividend investor may take a look at NASDAQ:GILD.

Uncovering Dividend Opportunities with GILEAD SCIENCES INC (NASDAQ:GILD).

News Image4 days ago - Market News VideoKKR Moves Up In Market Cap Rank, Passing Gilead Sciences
News Image4 days ago - The Motley FoolBetter Growth Play: Merck or The Vanguard Growth Index Fund?

Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?

News Image4 days ago - The Motley FoolShould You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?

Dividend stocks can be a smart way to ride out market volatility.

News Image8 days ago - Market News VideoGILD May 31st Options Begin Trading
News Image8 days ago - FinancialNewsMediaBiotech Innovations Paving the Way in Breast Cancer Fight

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END

News Image8 days ago - USA News GroupBiotech Innovations Paving the Way in Breast Cancer Fight

/PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases,...

News Image10 days ago - InvestorPlace3 Stocks at 52-Week Lows Poised for a Powerful Rebound

Starbucks, Gilead, and Vale are three stocks at 52-week lows that show signs of recovery potential and long-term growth prospects.

GILD Links
Follow us for more